IN THE CLAIMS:

Please cancel claims 1-32 and add new claims 33-47 as follows:

33. (New) A method for the treatment of a disease selected from the group consisting of transplantation rejection, host v. graft disease, graft v. host disease, leukemia/lymphoma, hyperproliferative vascular disorder, autoimmune disease, inflammatory disease, solid tumors, and fungal infection, comprising administering to an animal in need thereof an effective amount of glycosylated deuterorapamycin or a pharmaceutically acceptable salt thereof.

34. (New) The method of claim 33 wherein the glycosylated deuterorapamycin is glycosylated at the 42 position.

35. (New) The method of claim 33 wherein the glycosylated deuterorapamycin has the structure:



36. (New) The method of claim 33 wherein the disease is selected from the group consisting of transplantation rejection, host v. graft disease, graft v. host disease, autoimmune disease, and inflammatory disease.

37. (New) The method of claim 33 wherein the disease is selected from the group consisting of leukemia/lymphoma, hyperproliferative vascular disorder, and solid tumors.

38. (New) The method of claim 33 wherein the disease is a fungal infection.

39. (New) The method of claim 33 wherein the animal in need is a human.

40. (New) The method of claim 33 wherein the glycosylated deuterorapamycin or pharmaceutically acceptable salt thereof is administered as a pharmaceutical composition comprising the glycosylated deuterorapamycin or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

41. (New) The method of claim 40 wherein the pharmaceutically acceptable carrier is selected from the group consisting essentially of a solid carrier and a liquid carrier.

42. (New) The method of claim 40 wherein the pharmaceutically acceptable carrier is a solid carrier.

43. (New) The method of claim 40 wherein the pharmaceutically acceptable carrier is a liquid carrier.

44. (New) The method of claim 40 wherein the pharmaceutical composition is in unit dosage form.

45. (New) The method of claim 40 wherein the pharmaceutical composition is in tablet form.

46. (New) The method of claim 38 wherein the glycosylated deuterorapamycin or pharmaceutically acceptable salt thereof is administered as a pharmaceutical composition wherein the glycosylated deuterorapamycin or pharmaceutically acceptable salt thereof is a formulation selected from the group consisting of a solution, a cream, and a lotion.

47. (New) The method of claim 33 wherein the glycosylated deuterorapamyin or pharmaceutically acceptable salt thereof is administered intramuscularly, intraperitoneally, subcutaneously, intravenously, orally, or topically.